Dar Bioscience Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Dar Bioscience Inc 's ROA in the second quarter of 2026?
Dar Bioscience Inc recorded a cumulative net loss of $-11 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -39.08%.

However, within the Healthcare sector 474 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3881, from total ROA ranking in the first quarter of 2026 at 4664.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	70.04 %	49.46 %	44.34 %	69.79 %	-45.02 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-11	-12	-13	-16	-17
Return On Assets (TTM)	-39.08 %	-46.52 %	-56.92 %	-75.92 %	-95.6 %
DARE's Total Ranking	# 3881	# 4664	# 4252	# 4438	# 2757
Total Assets (TTM) in million	22	28	32	31	13
Seq. Total Assets Change	-20.69 %	-12.77 %	4.04 %	136.23 %	-30.29 %
Seq. Net Income Change	-	-	-	-	-

DARE's 5 Years Annual ROA >> Back to DARE Management Effectiveness >> Compare DARE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 188
Sector	# 475
Overall	# 3738

Return On Assets Statistics
High	Average	Low
25.36 %	-105.6 %	-355.43 %
(Dec 31 2017)		(Mar 31 2021)

Financial Statements
Dar Bioscience Inc 's Assets	$ 22 million	DARE's Balance sheet
Dar Bioscience Inc 's Income	$ -3 million	Quarterly DARE's Income Statement
DARE's Income by Division		See DARE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	46.94 %	3.85 %	-51.44 %	-21.47 %	639.1 %
Total Assets in million	32	22	21	44	56
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	-4	-30	-31	-39
Annual Return On Assets	-41.26 %	-18.34 %	-141.72 %	-70.61 %	-69.34 %

DARE's 5 Years Annual ROA >> Back to DARE Management Effectiveness >> Compare DARE ROA to its Competitors

More Return On Assets Ratios
DARE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DARE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DARE's Competitors
Subscribers only: Roa for Dar Bioscience Inc 's Suppliers
Subscribers only: Return On Assets for DARE's Customers

You may also want to know
DARE's Roi	DARE's Inventory Turnover Ratio	DARE's Growth Rates	DARE's Dividend Comparisons
	DARE's Profitability Ratios	DARE's Asset Turnover Ratio	DARE's Dividend Growth
DARE's Roe	DARE's Valuation Ratios	DARE's Financial Strength Ratios	DARE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T11:42:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.